Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05326815 · ClinicalTrials.gov registry record
A Comparison of Serum and Urine N-telopeptide Marker
A clinical trial, sponsored by The Cleveland Clinic.
- Completed
- Registry status
- 54
- Enrollment target
NCT05326815: Completed study, sponsored by The Cleveland Clinic.
NCT05326815 is a clinical trial that has completed, run by The Cleveland Clinic. The registered enrollment target is 54 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05326815 has completed, sponsored by The Cleveland Clinic.
- COMPLETED
- Registry status
- 54 participants
- Enrollment target
Study Summary
This is a prospective specimen collection cohort study to evaluate the correlation between serum and urine values of the bone marker of interest, and their association with baseline DEXA scan measures and fracture risk within 6 months. Study samples will be obtained longitudinally. One collection of both serum and urine collection will be obtained. The urine will be collected as second void of day and at the same time the blood collection is drawn. Study will continue for a period or 1 year, with plan to enroll around 40 subjects.
Primary Outcome
Correlation between NTX measures with each other
Interventions
- DIAGNOSTIC_TEST N-Telopeptide, Bone Marker
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2022-06-23 |
| Est. Completion | 2023-10-27 |
What the finished NCT05326815 record still lists
NCT05326815 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 54 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which N-Telopeptide, Bone Marker is the first listed.
NCT05326815 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05326815 about?
NCT05326815 is a clinical study titled "A Comparison of Serum and Urine N-telopeptide Marker". This is a prospective specimen collection cohort study to evaluate the correlation between serum and urine values of the bone marker of interest, and their association with baseline DEXA scan measures and fracture risk within 6 months. Study samples will be obtained longitudinally. One collection o...
What is the current status of trial NCT05326815?
This trial is currently completed. The enrollment target is 54 participants. The study started on 2022-06-23. Estimated completion is 2023-10-27.
What interventions are being tested in trial NCT05326815?
The interventions under investigation include: N-Telopeptide, Bone Marker (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05326815?
This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01269853 · 54 participants · Phase 1
Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA
- NCT02390752 · 54 participants · Phase 1
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
- NCT02991248 · 54 participants · NA
Improve Dynamic Lateral Balance of Humans With SCI
- NCT02993900 · 54 participants · NA
Image-Guided Gynecologic Brachytherapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI